SCHEDULE 13G: Soleus Capital Discloses 5.2% Passive Stake in STAAR Surgical Company

Soleus Capital Master Fund, L.P. and its affiliated entities have reported a passive beneficial ownership of 5.2% in STAAR Surgical Company, totaling 2,562,893 shares.

Summary

• Soleus Capital Master Fund, L.P., along with its general partner Soleus Capital, LLC, managing member Soleus Capital Group, LLC, investment manager Soleus Capital Management, L.P., its general partner Soleus GP, LLC, and Guy Levy (managing member of Soleus Capital Group, LLC and Soleus GP, LLC), have jointly filed a Schedule 13G.
• The filing discloses a beneficial ownership of 2,562,893 shares of common stock in STAAR Surgical Company.
• This ownership represents 5.2% of STAAR Surgical Company's outstanding common stock.
• The percentage is calculated based on 49,325,372 shares of STAAR Surgical Company common stock outstanding as of February 18, 2025, as reported in the Issuer's Annual Report on Form 10-K for the fiscal year ended December 27, 2024, filed on March 21, 2025.
• All reporting persons share both voting and dispositive power over the 2,562,893 shares.
• The filing indicates a passive investment, with the reporting persons certifying that the securities were not acquired and are not held for the purpose of changing or influencing the control of STAAR Surgical Company.

Sentiment

Score: 6

Explanation: The filing is primarily a factual compliance disclosure of a significant passive ownership stake. The presence of a new institutional investor holding over 5% can be viewed as a moderately positive signal of confidence in the issuer, without implying any immediate operational or financial changes.

Positives

• The disclosure of a significant 5.2% stake by an institutional investor like Soleus Capital may signal confidence in STAAR Surgical Company's long-term prospects.
• The passive nature of the investment, as stated in the filing, suggests that the investor is not seeking to influence management or control, which can provide stability.

Risks

• The reporting persons disclaim beneficial ownership of the shares for any purpose other than determining their obligations under Section 13(d) of the Exchange Act, which is a standard legal disclaimer but highlights the limited scope of their disclosed interest.

Future Outlook

This Schedule 13G filing is an ownership disclosure and does not contain any forward-looking statements or guidance regarding STAAR Surgical Company's future performance or outlook.

Industry Context

STAAR Surgical Company operates in the medical device industry, specializing in ophthalmic surgical products. The investment by Soleus Capital, an investment fund, indicates continued institutional interest in the medical technology sector, particularly in companies with established products like STAAR Surgical's implantable lenses.

Corporate Governance

Related Party Transactions

• The filing details the hierarchical relationship among the Soleus Capital entities (Soleus Capital Master Fund, L.P., Soleus Capital, LLC, Soleus Capital Group, LLC, Soleus Capital Management, L.P., Soleus GP, LLC) and Guy Levy, clarifying how beneficial ownership of STAAR Surgical shares is attributed through this organizational structure.

Stakeholder Impact

• Shareholders: Gain transparency on a new significant institutional investor holding a 5.2% stake, which may be viewed positively as a sign of institutional confidence.
• Management: Awareness of a new large passive shareholder, though the filing explicitly states no intent to influence control.

Key Dates

Keywords

STAAR Surgical Company, Soleus Capital, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Passive Investment, Medical Devices, Ophthalmology, SEC Filing